Skip to main content

Table 3 Adverse events in the safety set with incidence ≥15% in the everolimus arm of he Asian or non-Asian subset

From: Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1

Adverse event, %

Asian

Non-Asian

EVE + TRAS + PAC

PBO + TRAS + PAC

EVE + TRAS + PAC

PBO + TRAS + PAC

n = 196

n = 104

n = 276

n = 134

Any grade

Grade 3

Grade 4

Any grade

Grade 3

Grade 4

Any grade

Grade 3

Grade 4

Any grade

Grade 3

Grade 4

Stomatitis

62.2

6.6

0.0

31.7

0.0

0.0

69.6

16.7

0.0

32.8

2.2

0.0

Diarrhea

48.0

6.1

0.0

40.4

3.8

0.0

62.7

11.2

0.0

51.5

4.5

0.0

Rash

43.4

1.0

0.0

24.0

1.0

0.0

38.0

0.4

0.0

17.9

0.0

0.0

Neutropenia

42.3

27.6

4.6

26.9

17.3

3.8

34.1

16.7

2.9

23.1

5.2

4.5

Alopecia

41.3

0.0

0.0

41.3

0.0

0.0

50.7

0.4

0.0

61.2

0.0

0.0

Pyrexia

39.8

0.5

0.0

26.0

1.0

0.0

38.4

2.2

0.0

26.9

1.5

0.0

Cough

38.3

0.5

0.0

35.6

0.0

0.0

41.3

0.4

0.0

30.6

1.5

0.0

Fatigue

33.2

3.1

0.0

29.8

1.9

0.0

36.6

6.2

0.0

40.3

3.0

0.0

Epistaxis

29.1

0.0

0.0

10.6

0.0

0.0

36.2

0.0

0.0

23.1

0.0

0.0

Edema peripheral

28.6

0.0

0.0

17.3

1.0

0.0

36.2

1.4

0.0

29.9

0.0

0.0

ALT increased

28.1

5.1

0.0

26.9

6.7

0.0

15.6

6.5

0.0

11.9

3.0

0.7

Nasopharyngitis

27.0

0.0

0.0

30.8

1.9

0.0

12.7

0.0

0.0

11.2

0.0

0.0

Nausea

26.0

0.5

0.0

25.0

1.9

0.0

37.3

1.1

0.0

41.8

0.0

0.0

Hypoesthesia

23.5

3.1

0.0

26.9

1.9

0.0

5.4

0.0

0.0

5.2

0.0

0.0

Mouth ulceration

23.0

1.0

0.0

10.6

0.0

0.0

5.4

0.7

0.0

1.5

0.0

0.0

Decreased appetite

22.4

1.0

0.0

16.3

0.0

0.0

23.9

1.4

0.0

13.4

0.0

0.0

Myalgia

22.4

0.0

0.0

25.0

1.0

0.0

12.0

0.0

0.0

14.2

0.0

0.0

Neutrophil count decreased

21.9

11.2

3.6

20.2

12.5

1.9

0.4

0.4

0.0

1.5

0.0

0.0

Headache

20.9

1.0

0.0

18.3

1.9

0.0

33.0

0.4

0.0

37.3

0.0

0.0

Leukopenia

20.4

8.7

0.5

14.4

5.8

1.0

11.6

4.0

0.4

6.7

3.0

0.0

Neurotoxicity

19.9

0.0

0.0

22.1

1.0

0.0

0.4

0.0

0.0

0.7

0.0

0.0

Insomnia

19.9

0.0

0.0

11.5

0.0

0.0

13.8

0.0

0.0

20.1

0.0

0.0

Vomiting

19.4

1.0

0.0

20.2

1.9

0.0

30.1

1.1

0.0

25.4

3.0

0.0

Dizziness

18.9

2.0

0.5

15.4

0.0

0.0

13.4

0.0

0.0

14.9

1.5

0.0

Weight decreased

18.9

0.5

0.0

4.8

0.0

0.0

22.5

2.2

0.0

5.2

0.0

0.0

AST increased

18.4

2.6

0.0

14.4

3.8

0.0

13.8

4.0

0.7

9.0

0.7

0.7

Dyspnea

17.3

2.0

0.0

1.0

0.0

0.0

29.3

4.3

0.7

17.2

1.5

0.0

Constipation

16.3

0.0

0.0

18.3

0.0

0.0

25.0

0.0

0.0

23.1

0.0

0.0

Peripheral sensory neuropathy

15.8

0.5

0.0

18.3

0.0

0.0

11.6

0.7

0.0

12.7

1.5

0.0

Pruritus

15.8

0.5

0.0

8.7

0.0

0.0

12.0

0.4

0.0

11.2

0.0

0.0

WBC count decreased

15.3

9.7

0.5

12.5

7.7

0.0

1.1

0.7

0.0

0.7

0.0

0.0

Oropharyngeal pain

15.3

0.0

0.0

11.5

0.0

0.0

15.9

0.0

0.0

14.2

0.0

0.0

Arthralgia

13.8

0.0

0.0

11.5

0.0

0.0

19.2

1.4

0.0

21.6

1.5

0.0

Anemia

13.3

5.6

1.0

7.7

1.9

0.0

43.5

10.5

1.4

22.4

3.0

0.0

Hypercholesterolemia

12.8

0.5

0.0

7.7

0.0

0.0

22.5

1.4

0.0

11.2

0.0

0.0

Neuropathy peripheral

12.8

0.5

0.0

15.4

3.8

0.0

40.2

6.2

0.0

31.3

5.2

0.0

Pneumoniaa

12.2

1.5

1.0

4.8

0.0

0.0

7.6

2.9

0.0

3.7

0.0

0.0

Pneumonitisa

12.2

2.0

0.0

2.9

0.0

0.0

19.2

5.4

1.4

5.2

0.7

0.0

Hyperglycemiaa

11.7

4.6

1.0

1.9

1.0

0.0

14.1

5.8

0.7

8.2

1.5

0.0

Pain in extremity

11.7

0.5

0.0

12.5

0.0

0.0

22.5

1.4

0.4

18.7

0.0

0.0

Back pain

11.2

1.0

0.0

11.5

1.0

0.0

18.1

1.1

0.0

21.6

3.0

0.0

Hypertension

11.2

2.6

0.0

11.5

1.0

0.0

17.8

2.2

0.0

10.4

2.2

0.0

Hypokalemia

10.7

5.1

0.5

2.9

2.9

0.0

17.0

7.2

2.2

3.7

0.0

0.0

Abdominal pain

10.7

1.5

0.0

9.6

0.0

0.0

18.1

0.4

0.0

14.2

0.0

0.0

Asthenia

9.2

2.0

0.0

8.7

0.0

0.0

26.8

1.4

0.0

23.9

1.5

0.0

Urinary tract infection

6.6

0.5

0.0

3.8

0.0

0.0

17.0

1.4

0.0

9.7

0.0

0.0

  1. aAdverse events of special interest. EVE everolimus, PAC paclitaxel, PBO placebo, TRAS trastuzumab, ALT alanine aminotransferase, AST aspartate aminotransferase, WBC white blood cell